[Correspondence] Stereotactic ablative radiotherapy for primary kidney cancer

The FASTRACK II study by Shankar Siva and colleagues1 provided short-term evidence of renal tumour sensitivity to high-dose radiation in the non-surgical treatment of T1 renal tumours.

[Correspondence] Dysphagia-optimised intensity-modulated radiotherapy versus standard radiotherapy in patients with pharyngeal cancer – Authors' reply
We thank the readers for their kind comments on our work. Ahitagni Biswas and colleagues…
[Comment] SERDs for primary breast cancer
In The Lancet Oncology, Sara A Hurvitz and colleagues1 report their randomised phase 2 trial,…
[Correspondence] Uncovering causal clues in the development of second primary cancers
We were intrigued by the Article by Trille Kristina Kjaer and colleagues1 on the cumulative…

For Additional News from OncWeekly – Your Front Row Seat To The Future of Cancer Care –

[Correspondence] Stereotactic ablative radiotherapy for primary kidney cancer

LATEST

Super T2-FLAIR Mismatch: Prognostic Marker for IDH-Astrocytomas

Efficacy of CRT Post Noncurative ESD in Esophageal SCC

NFF in Unresectable PC Shows Superior OS vs S-1

Axillary Node Prediction in BC With SLNB After NAC

Clinical Trial Portal

[Correspondence] Stereotactic ablative radiotherapy for primary kidney cancer

Related Posts

LATEST

Super T2-FLAIR Mismatch: Prognostic Marker for IDH-Astrocytomas

Efficacy of CRT Post Noncurative ESD in Esophageal SCC

NFF in Unresectable PC Shows Superior OS vs S-1

Axillary Node Prediction in BC With SLNB After NAC

Sign up for our emails

Newsletter

Footer Newsletter